49.84

3.94% +1.89

(After Hours: 49.84 0 +0.00%)

News Options Financials Holders Transactions Discussions Predictions

Apr-22-21 04:01AM	Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021GlobeNewswire
Apr-21-21 08:50AM	Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B StudyBenzinga
08:00AM	Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis BBusiness Wire
Apr-21-21 06:52AM	What's in the Cards for Eli Lilly (LLY) This Earnings Season?Zacks
Apr-17-21 06:00AM	Could Vir Biotechnology Be a Millionaire Maker Stock?Motley Fool
Apr-16-21 07:14AM	Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EUZacks
Apr-15-21 09:51AM	GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19GlobeNewswire
08:59AM	UPDATE 2-EMA starts review of GSK's monoclonal antibody to treat COVID-19 patientsReuters
Apr-08-21 08:30AM	Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host CellsGlobeNewswire
Apr-06-21 04:01AM	Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
Apr-05-21 09:08AM	Vir Biotech's VIR-7831 Maintains Activity Against California Variant Of COVID-19 InfectionBenzinga
08:00AM	Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California VariantGlobeNewswire
Mar-31-21 01:33AM	Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & MoreZacks
Mar-29-21 08:44AM	Eli Lilly, Vir and Glaxo say Phase 2 trial combining antibodies reduced viral load by 70% at day 7MarketWatch
08:30AM	Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19GlobeNewswire
Mar-26-21 12:42PM	GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 DrugBenzinga
08:40AM	GlaxoSmithKline and Vir Biotech seek FDA emergency authorization for COVID antibody treatmentMarketWatch
Mar-26-21 08:30AM	GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19GlobeNewswire
Mar-25-21 10:55AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRACCESSWIRE
Mar-24-21 01:03AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRPR Newswire
Mar-21-21 10:29AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRNewsfile
Mar-18-21 05:13AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRPR Newswire
Mar-16-21 10:33AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRACCESSWIRE
02:09AM	Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & MoreZacks
Mar-16-21 07:35AM	AstraZeneca to supply U.S. with extra 500,000 doses of COVID-19 antibody-based cocktailMarketWatch
Mar-14-21 09:21AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRNewsfile
06:35AM	Can Vir Biotechnology Distinguish Itself In The Vaccine Market?TipRanks
Mar-12-21 09:33AM	Vir Biotech (VIR)/Glaxo COVID-19 Drug Cuts Hospitalization RiskZacks
08:04AM	Vir Biotechnology, Inc. (VIR) Surges 32.1%: Is This an Indication of Further Gains?Zacks
Mar-12-21 06:20AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRPR Newswire
Mar-11-21 05:12AM	Why Vir Biotechnology Stock Soared TodayMotley Fool
04:18AM	Biotech Stock Catapults After GSK-Partnered Covid Drug Succeeds In Key TestInvestor's Business Daily
Mar-11-21 12:01PM	Biotech Stock Catapults After GSK-Partnered Covid Drug Succeeds In Key TestInvestor's Business Daily
09:25AM	Vir Stock Catapults After Its GSK-Partnered Covid Drug Succeeds In New TestInvestor's Business Daily
Mar-11-21 08:38AM	Vir’s Covid-19 Antibody Works Well, Sending Shares FlyingBarrons.com
08:19AM	The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From ProthenaBenzinga
Mar-11-21 06:45AM	Vir Biotech Soars as Covid Therapy Found Effective at Cutting DeathsInvesting.com
05:13AM	Vir/GSK's COVID-19 Antibody Therapy Cuts Hospitalization, Deaths by 85%, Seeks FDA Emergency Use NodBenzinga
Mar-10-21 08:22AM	Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19GlobeNewswire
12:05PM	New Forecasts: Here's What Analysts Think The Future Holds For Vir Biotechnology, Inc. (NASDAQ:VIR)Simply Wall St.
Mar-07-21 08:55AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRNewsfile
Mar-05-21 09:04AM	Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to FluMotley Fool
07:54AM	NIH stops clinical trials for two experimental antibody COVID-19 treatmentsMarketWatch
Mar-04-21 02:47AM	Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & MoreZacks
12:52PM	Why Vir Biotechnology Stock Is Falling TodayMotley Fool
Mar-04-21 10:27AM	U.S. COVID death toll above 518,000 as Biden adds voice to outrage at Texas and Mississippi for reopeningMarketWatch
08:35AM	Are Options Traders Betting on a Big Move in Vir Biotechnology (VIR) Stock?Zacks
Mar-04-21 08:29AM	NIH tells Vir that experimental COVID-19 therapy may not benefit patientsMarketWatch
Mar-03-21 04:35AM	Vir Stock Craters On Weak Results For Glaxo-Partnered Covid TreatmentInvestor's Business Daily
02:57AM	Vir Shares Plummeted Today. What to Know.Barrons.com

Vir Biotechnology (VIR) Stock Discussions on Social Media

- VIR Stock on Twitter: https://twitter.com/search?q=$vir
- VIR Stock on Reddit: https://www.reddit.com/search/?q=$vir
- VIR Stock on SeekingAlpha: https://seekingalpha.com/symbol/VIR

More Discussions

edward · April 19, 2021

Eli Lilly applied EUA 7th October Obtained EUA 9 November. Took 24 daysRegeneron applied EUA 8th Obtained 21 November. Took 33 daysI suggest EUA will take between 24 - 33 days. Anticipated date: 28 April - 11 May

Upvote: 4 · Downvote: 0 · Replies: 0

Gauri · April 19, 2021

The U.S. Food and Drug Administration last year authorized Regeneron Pharmaceuticals' (NASDAQ:REGN) antibody cocktail for the same patient group. In recent trial data, Regeneron showed its cocktail cut the risk of hospitalization or death by 70%. Treatment with the VIR-7931 monoclonal antibody resulted in an 85% decrease in hospitalization or death. Vir's performance will give it an edge over Regeneron. And it also involves a lower dosage -- 500 mg. Regeneron's dosages start at 1,200 mg.

Upvote: 8 · Downvote: 0 · Replies: 0

Gauri · April 17, 2021

GlaxoSmithKline(GSk) and VIR announced that European Medical Association(EMA) has started review of VIR-7831 and will provide recommendations for national authorities who may make early evidence based decisions on the early use of medicine ahead of any formal marketing authorisation.

Upvote: 2 · Downvote: 0 · Replies: 0

Cal G · April 17, 2021

FDA announcement will probably be announced at 2:33 am. Saturday morning when everyone is asleep.

Upvote: 7 · Downvote: 2 · Replies: 0

Julie · April 16, 2021

Don’t understand this downward trend

Upvote: 1 · Downvote: 0 · Replies: 0

Marta · April 16, 2021

This is going to be a massive jump with VIR, we might see $150 per share within 30 days

Upvote: 1 · Downvote: 1 · Replies: 0

Marta · April 16, 2021

Just bought another 15k shares, up we go!!

Upvote: 2 · Downvote: 0 · Replies: 0

V · April 16, 2021

The price is clearly manipulated to the downside. The stock has returned to the same level it was BEFORE announcing one of the most promising cures for COVID-19...

Upvote: 1 · Downvote: 2 · Replies: 0

edward · April 16, 2021

Expect EUA 22 April !

Upvote: 3 · Downvote: 0 · Replies: 0

Marta · April 14, 2021

FDA approval just about here!!! Let's go!

Upvote: 1 · Downvote: 0 · Replies: 0

Gauri · April 14, 2021

Fda approval now expected anyday!

Upvote: 2 · Downvote: 0 · Replies: 0

CCN · April 13, 2021

VIR SP can pop anytime...be prepared!

Upvote: 0 · Downvote: 0 · Replies: 0

Heag · April 13, 2021

this stock will go down to nothing!

Upvote: 2 · Downvote: 1 · Replies: 0

Gauri · April 13, 2021

Two vaccines AstraZeneca and J&J going out because of side effects. VIR-7831 will be soon in the winning race as soon as it gets FDA approval and it’s also effective against California variant.

Upvote: 0 · Downvote: 0 · Replies: 0

Gauri · April 12, 2021

Success of VIR - 7831 is phenomenal. The effects of monoclonal antibody treatments are more prompt and assured and faster than vaccines. They can work on their own or complement vaccines to speed up the process. And this tech can be used not only for combating covid but many other infectious diseases as well. Going to revolutionise the medical industry. As soon as it gets FDA approval it’s going to benefit millions. And make this stock among high flying biotech stocks. Soooon!

Upvote: 1 · Downvote: 3 · Replies: 0

Gauri · April 11, 2021

Dr Alexander Edwards, Associate Professor in Biomedical Technology, Reading School of Pharmacy, University of Reading, said:The success of VIR-7831 is spectacular and this new medicine would complement vaccines and other new treatments to make major reductions to the terrible impact of COVID-19.“This class of drug could be especially important for those people who are less protected by vaccines for example if their immune system is weakened (as recently discussed for some cancer patients) – we can supplement their own immunity with this “extra” antibody against the virus.“One reason this is so exciting is that it may herald a “breakthrough” for this class of medicines – monoclonal antibody treatment of viral infection. Monoclonal antibody drugs provide ‘artificial immunity’ by manufacturing antibodies in a bioreactor. In contrast vaccines trigger your body to make your own antibodies (and other immune responses). Monoclonal antibody drugs have been most widely used to treat cancer and autoimmunity, but have always had enormous potential to directly combat an infection. If the headline 85% reduction in hospitalisation or death translates into widespread use, this will deliver on the great promise of monoclonal antibodies to treat infections.

Upvote: 2 · Downvote: 0 · Replies: 0

Санек · April 11, 2021

When we should wait answer from FDA, who have their number of telephone? I will call them and ask how long time we will wait?

Upvote: 0 · Downvote: 0 · Replies: 0

Gauri · April 11, 2021

They have an amazing lineup of scientists and management. Just in a short while they have come so far. Going to go really high.Patience is the key here. Only for a while. Hold on to your shares.

Upvote: 0 · Downvote: 0 · Replies: 0

donald · April 11, 2021

buy buy buy EUA coming then IM shot.. PPS will once again go above 100

Upvote: 1 · Downvote: 1 · Replies: 0

Julie · April 08, 2021

Why does this tank every day?

Upvote: 0 · Downvote: 0 · Replies: 0

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.

List of Zack Morris Stocks List of SPAC Stocks List of EV Stocks and Related Stocks Top 100 popular stocks on Robinhood List of Marijuana Stocks

Open in Yahoo | Open in Google | Open in Finviz